Steece-Collier awarded up to $2M from neuroscience nonprofit for Parkinson’s research
April 3, 2025
SPARK NS, an independent nonprofit dedicated to advancing discoveries in neuroscience, has announced that Kathy Steece-Collier, PhD, has been named a recipient of up to $2M to further her project titled “A Disease Modifying Gene Therapy for Parkinson’s Disease for Multimodal Patient Benefit.”
Steece-Collier, a professor in the Department of Translational Neuroscience, is one of eight recipients named in the $16M award announced by SPARK NS Thursday morning. All the projects selected for the SPARK NS Translational Research Program, 2025 Cohort focus on Parkinson’s disease.
For decades, Steece-Collier has led an effort to reduce or eliminate dyskinesia, the involuntary and uncontrolled movement of hands, the head, and other body parts, which results as a side effect of commonly prescribed Parkinson’s drug. She and her all-woman team have a goal to render Parkinson’s a treatable disease where symptoms can be minimized and effectively managed, thereby improving the quality of life for patients.
SPARK NS aims to advance promising academic discoveries in neuroscience from the lab to the clinic, eliminating barriers between revelations and treatments. The SPARK NS program offers academic researchers funding, education in drug development, mentorship by industry experts, and networking opportunities.
Read the SPARK NS announcement.
Related News
New therapeutic offers hope for patients with Parkinson's disease.